Wellington Management Group LLP Sells 726,201 Shares of Zoetis Inc. $ZTS

Key Points

• Wellington Management Group reduced its Zoetis stake by 7.2%, selling 726,201 shares and retaining 9.42 million shares valued at approximately $677.2 million.
• Institutional investors own 92.8% of Zoetis, with several firms—including Deutsche Bank and Diamond Hill Capital—adding to their positions during recent quarters.
• Analyst sentiment is mixed, with a consensus “Hold” rating and average price target of $107.43. Zoetis reported quarterly EPS of $1.87, slightly above estimates, while revenue declined 0.2% year over year to $2.47 billion.

Wellington Management Group LLP cut its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 7.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,423,895 shares of the company's stock after selling 726,201 shares during the quarter. Wellington Management Group LLP owned approximately 2.28% of Zoetis worth $677,201,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Louisiana State Employees Retirement System bought a new stake in shares of Zoetis during the first quarter worth $2,542,000. Wealthfront Advisers LLC lifted its stake in shares of Zoetis by 80.2% in the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company's stock valued at $5,469,000 after acquiring an additional 33,873 shares during the last quarter. Deutsche Bank AG boosted its holdings in shares of Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company's stock valued at $699,331,000 after acquiring an additional 891,921 shares in the last quarter. Pincus Capital Management LP acquired a new stake in shares of Zoetis during the 4th quarter valued at $2,109,000. Finally, Diamond Hill Capital Management LLC Investment Advisor grew its position in Zoetis by 21.5% during the 2nd quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company's stock worth $255,637,000 after acquiring an additional 629,974 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

ZTS has been the subject of a number of research reports. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a report on Tuesday. Stifel Nicolaus reduced their target price on shares of Zoetis from $85.00 to $80.00 and set a "hold" rating on the stock in a report on Thursday, August 20th. JPMorgan Chase & Co. decreased their price target on shares of Zoetis from $130.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. Wall Street Zen lowered shares of Zoetis from a "buy" rating to a "hold" rating in a report on Saturday, May 2nd. Finally, Barclays reduced their price objective on shares of Zoetis from $136.00 to $85.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 1st. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $107.43.

Zoetis Price Performance

Zoetis stock opened at $77.45 on Friday. The stock's 50 day moving average is $75.57 and its 200 day moving average is $95.62. Zoetis Inc. has a one year low of $71.00 and a one year high of $156.49. The firm has a market cap of $32.00 billion, a P/E ratio of 12.76, a P/E/G ratio of 1.80 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts' consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the firm posted $1.76 EPS. The company's revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.2 EPS for the current year.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source